Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoART: Neoadjuvant Artesunate in Colorectal Cancer
NCT02633098Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Countries
- 1
- Sponsor
- St George's, University of London
- Modality
- Small Molecules
- Drugs
- artesunate
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, randomised, double-blind trial of artesunate in colorectal cancer (CRC), sponsored by St George's, University of London. Primary endpoint: Recurrence-Free Survival at 2 years. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 18+ with Stage II/III colorectal adenocarcinoma planned for surgery, with adequate organ function and no indication for standard neoadjuvant chemo/radiotherapy.
04
Endpoints
Primary
Recurrence-Free Survival
Beyond the preview
Go deeper on NCT02633098.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633098.